• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Cipla Ltd.
    27 Jun 2024
    1560.80
    -0.19%
    Cipla - Classification Of Goa Inspection Remains Key: Motilal Oswal
    Cipla - Classification Of Goa Inspection Remains Key: Motilal Oswal
    NDTV Profit
    Comprehensive measures required to resolve regulatory issues
    Copy LinkShare onShare on Share on Share on
    Cipla Ltd. is trading above all available SMAs
    logo
    Alkem Laboratories Ltd.
    25 Jun 2024
    5393.50
    1.37%
    Alkem Laboratories Promoter Offloads Stake For Rs 177 Crore
    Alkem Laboratories Promoter Offloads Stake For Rs 177 Crore
    NDTV Profit
    Seema Singh offloaded 3.58 lakh shares at Rs 4,956 apiece, according to the block deal data on the NSE.
    Copy LinkShare onShare on Share on Share on
    Alkem Laboratories Ltd. is trading above all available SMAs
    Alkem Labs shares surge 5% on USFDA's VAI status for Baddi facility
    Business Standard | 25 Jun 2024
    logo
    Ajanta Pharma Ltd.
    25 Jun 2024
    2572.00
    -0.84%
    Broker's call: Ajanta Pharma (Add)
    Business Line
    InCred Equities
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 385 to 371 in Jun 2025 qtr
    logo
    GlaxoSmithKline Pharmaceuticals Ltd.
    25 Jun 2024
    2863.80
    0.93%
    New product launches may continue to fuel GSK Pharma's robust growth
    Business Standard
    GSK Pharma's recent good showing is on expectations that launches in the specialty segment, increasing investments in promotions and branding
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 340 to 390 in Jun 2025 qtr.
    logo
    AstraZeneca Pharma India Ltd.
    25 Jun 2024
    9071.50
    0.84%
    AstraZeneca's Imfinzi fails in late-stage trial to treat lung cancer cases
    Business Standard
    Imfinzi is a human monoclonal antibody, which works to block a tumour's ability to evade and dampen the immune system, while also boosting the body's anti-cancer immune response
    Copy LinkShare onShare on Share on Share on
    Number of MF schemes increased from 53 to 60 in Jun 2025 qtr.
    logo
    Sun Pharmaceutical Industries Ltd.
    24 Jun 2024
    US FDA Classification
    1609.70
    1.02%
    Sun Pharma Finalises Acquisition Of Taro For $347.73 Million
    Sun Pharma Finalises Acquisition Of Taro For $347.73 Million
    NDTV Profit
    Taro has become a privately held company and is now a wholly owned subsidiary of Sun Pharma.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 1351 to 1326 in Jun 2025 qtr
    logo
    GlaxoSmithKline Pharmaceuticals Ltd.
    24 Jun 2024
    2863.80
    0.93%
    GSK Pharma - Business In Recovery Model: Motilal Oswal
    GSK Pharma - Business In Recovery Model: Motilal Oswal
    NDTV Profit
    Valuation adequately factors in the earnings upside
    Copy LinkShare onShare on Share on Share on
    GlaxoSmithKline Pharmaceuticals Ltd. is trading below its 50 day SMA of 2965.0
    logo
    Cipla Ltd.
    24 Jun 2024
    1560.80
    -0.19%
    Cipla Hits Two-Week Low After FDA Flags Issues At Goa Facility
    Cipla Hits Two-Week Low After FDA Flags Issues At Goa Facility
    NDTV Profit
    The stock declined as much as 3.02% during the day to Rs 1,495.05 apiece on the NSE.
    Copy LinkShare onShare on Share on Share on
    Deven Choksey released a Hold report for Cipla Ltd. with a price target of 1570.0 on 08 Sep, 2025.
    logo
    Sun Pharmaceutical Industries Ltd.
    24 Jun 2024
    US FDA Classification
    1609.70
    1.02%
    Outperformance of private sector banks may continue for next one year: Sandip Sabharwal
    Outperformance of private sector banks may continue for next one year: Sandip Sabharwal
    Economic Times
    The smaller pharma companies I find it tough to evaluate, so many of them can potentially do well but I do not have the bandwidth to go molecule by molecule and evaluate those companies. But I think Sun Pharma is a decent business model, so we are just holding it for the long term.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 1351 to 1326 in Jun 2025 qtr
    logo
    Lupin Ltd.
    23 Jun 2024
    US FDA Observation
    1988.00
    0.42%
    Lupin, Eugia recall products from US market: USFDA
    Business Line
    As per the latest Enforcement Report issued by the USFDA, a US-based unit of Lupin is recalling a medication used to treat bacterial infections
    Copy LinkShare onShare on Share on Share on
    Lupin Ltd. is trading below its 200 day SMA of 2025.9
    Lupin, Eugia Recall Products From US Market Over Manufacturing Issues
    NDTV Profit | 23 Jun 2024 1 more
    Lupin, Eugia recall products from US over manufacturing issues: USFDA
    Business Standard | 23 Jun 2024
    more
    loading
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd